Latest Content

In this study, 13% of patients who stopped heart failure medications after successful AF ablation had HF deterioration vs none who continued treatment.

Medicare Advantage (MA) beneficiaries had similar optimal cancer treatment use and treatment timing as traditional Medicare (TM), with lower anticipated costs.

Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions.

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

Michigan has confirmed more than 1500 cyclospora cases as officials investigate the source of one of the nation's largest foodborne parasite outbreaks.

6 leading AI chatbots scored below 28% on a colorectal cancer knowledge test when barred from reasoning, raising fresh safety concerns for clinical use.

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.